ERBB2 and breast carcinoma: For example, Herceptin as a single agent or in combination with chemotherapy has been shown to reduce recurrent disease and to save lives in patients with HER2-positive breast cancer, yet a significant number of HER2 overexpression tumors do not respond to the treatment [11].